Investigation on the Anti-Cancer Effects of HER2-Targeted CAR-T Cells Engineered Using the <i>PiggyBac</i> Transposon System
These results highlight the potential of anti-HER2-13 CAR-T cells to serve as a safer and more efficacious alternative in HER2-targeted therapy.
Authors
- Hui Gao (ORCID: https://orcid.org/0000-0003-0162-2445)
- Shan He (ORCID: https://orcid.org/0000-0002-2698-0786)
- Yukun Guo (ORCID: https://orcid.org/0000-0002-6784-2355)
- Mingyao Meng (ORCID: https://orcid.org/0000-0002-9766-414X)
- Zongliu Hou (ORCID: https://orcid.org/0000-0003-3536-7550)
- Tiantian Li (ORCID: https://orcid.org/0000-0001-5940-3996)
- Lin Li (ORCID: https://orcid.org/0000-0002-8014-8296)
- Lili Yang
- Yuan Liu (ORCID: https://orcid.org/0009-0007-0993-4458)
- Yiyi Zhao
- Yu Zheng (ORCID: https://orcid.org/0000-0002-0968-5208)
- Lirong Yang
- Liwei Liao (ORCID: https://orcid.org/0000-0003-0152-8440)
- Xiao-Dan Wang
- Meng-Yuan Chu
- Wenju Wang
Institutions
- ShanghaiTech University (CN)
Publication Details
- Journal
- Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics
- Published
- 2025-01-01
- DOI
- https://doi.org/10.32604/or.2025.065394
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00